• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用完整的患者报告结局版常见不良事件术语标准(PRO-CTCAE)项目库的可行性评估。

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

机构信息

Princess Margaret Cancer Centre, Drug Development Program, University Health Network, Toronto, Canada.

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.

DOI:10.1634/theoncologist.2018-0332
PMID:30728278
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6459233/
Abstract

The patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) complements capture of symptomatic adverse events (AEs) by clinicians. Previous trials have typically used a limited subset of relevant symptomatic AEs to reduce patient burden. We aimed to determine the feasibility of administering all 80 AEs included in the PRO-CTCAE library by approaching consecutive patients enrolled in a large academic phase I program at three points in time. Here, we report a preplanned analysis after enrolling the first 20 patients. All items were answered on 51 of 56 potential visits (adherence 91%). Three (5%) additional PRO-CTCAE assessments were partially completed, and two (4%) were missed because of conflicting appointments. No patient withdrew consent or chose not to complete the assessments once enrolled on study. Future trials of experimental drugs that incorporate the PRO-CTCAE should consider using this unselected approach to identify adverse events more completely.

摘要

患者报告结局版常见不良事件术语标准(PRO-CTCAE)补充了临床医生对症状不良事件(AE)的捕捉。之前的试验通常使用有限的一组相关症状 AE 来减轻患者负担。我们旨在通过在三个时间点接近在三个大型学术 I 期计划中入组的连续患者,确定管理 PRO-CTCAE 库中包含的所有 80 个 AE 的可行性。在这里,我们报告了在入组前 20 名患者后的预先计划分析。在 56 个潜在访问中的 51 个(依从性 91%)回答了所有项目。由于预约冲突,有 3 项(5%)额外的 PRO-CTCAE 评估部分完成,有 2 项(4%)遗漏。一旦入组研究,没有患者撤回同意或选择不完成评估。未来的实验性药物试验如果纳入 PRO-CTCAE,应考虑使用这种未经选择的方法更全面地识别不良事件。

相似文献

1
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.使用完整的患者报告结局版常见不良事件术语标准(PRO-CTCAE)项目库的可行性评估。
Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.
2
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).使用美国国家癌症研究所的患者报告结局版常见不良事件术语标准(PRO-CTCAE),对癌症临床研究中的症状性不良事件进行患者自由文本报告。
J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.
3
Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.美国国家癌症研究所患者报告结局通用术语标准不良事件的韩语版的可靠性和有效性。
J Pain Symptom Manage. 2020 May;59(5):1082-1088.e6. doi: 10.1016/j.jpainsymman.2020.01.015. Epub 2020 Feb 8.
4
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
5
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.对美国国立癌症研究所的PRO-CTCAE不同召回期的评估。
Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.
6
Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).癌症临床试验中的患者报告结局:使用美国国立癌症研究所不良事件通用术语标准的患者报告结局版本(PRO-CTCAE)测量症状性不良事件。
Am Soc Clin Oncol Educ Book. 2016;35:67-73. doi: 10.1200/EDBK_159514.
7
Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.在肿瘤学试验的不良事件报告中引出儿童的声音:不良事件通用术语标准儿科患者报告结局版本的认知访谈结果
Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26261. Epub 2016 Sep 21.
8
Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.将儿童和青少年自我报告的症状数据与临床医生报告的不良事件分级进行映射,以改善儿科肿瘤学的护理和研究。
Cancer. 2020 Jan 1;126(1):140-147. doi: 10.1002/cncr.32525. Epub 2019 Sep 25.
9
Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局版(PRO-CTCAE)的丹麦语翻译及语言验证
J Pain Symptom Manage. 2016 Aug;52(2):292-7. doi: 10.1016/j.jpainsymman.2016.02.008. Epub 2016 Apr 15.
10
Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).德国患者报告的不良事件通用术语标准(PRO-CTCAE™)版本的验证。
Ann Oncol. 2016 Dec;27(12):2294-2299. doi: 10.1093/annonc/mdw422. Epub 2016 Sep 28.

引用本文的文献

1
Understanding the Role of Patient-Reported Outcomes for Decision-Making in Early-Phase Dose-Finding Clinical Trials.了解患者报告结局在早期剂量探索性临床试验决策中的作用。
Curr Oncol. 2025 Mar 19;32(3):176. doi: 10.3390/curroncol32030176.
2
Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion.经动脉化疗栓塞术与肝动脉灌注化疗作为伴有大血管侵犯的肝细胞癌的一线治疗方法比较
Int J Med Sci. 2025 Feb 24;22(6):1415-1424. doi: 10.7150/ijms.108144. eCollection 2025.
3
Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients.移民背景对晚期尿路上皮癌患者电子患者报告结局可行性的影响。
Health Qual Life Outcomes. 2024 Dec 18;22(1):107. doi: 10.1186/s12955-024-02325-z.
4
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.基于基因型的伊立替康剂量指导下的纵向患者报告结局:可行性和临床相关性。
Oncologist. 2024 Sep 6;29(9):780-785. doi: 10.1093/oncolo/oyae121.
5
Unleashing patient voices: empowering adverse event assessment with complete patient-reported outcomes.释放患者声音:通过完整的患者报告结局来增强不良事件评估。
Oncologist. 2024 Jul 5;29(7):e953-e956. doi: 10.1093/oncolo/oyae105.
6
Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review.癌症临床试验中的不良事件报告:纳入患者报告方法。系统范围综述。
Patient. 2024 Jul;17(4):335-347. doi: 10.1007/s40271-024-00689-4. Epub 2024 Apr 8.
7
Recommendations to address respondent burden associated with patient-reported outcome assessment.关于减轻与患者报告结局评估相关的应答负担的建议。
Nat Med. 2024 Mar;30(3):650-659. doi: 10.1038/s41591-024-02827-9. Epub 2024 Feb 29.
8
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.定制的 I 期特定患者报告结局(PRO)调查,以捕捉症状性不良事件的患者体验。
Br J Cancer. 2023 Sep;129(4):612-619. doi: 10.1038/s41416-023-02307-w. Epub 2023 Jul 7.
9
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials.国际生活质量研究学会对美国食品和药物管理局关于癌症临床试验中核心患者报告结局的行业指南草案的评论。
Qual Life Res. 2023 Aug;32(8):2155-2163. doi: 10.1007/s11136-023-03396-z. Epub 2023 May 23.
10
Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE to Provide Two Distinct and Complementary Perspectives.癌症临床试验中有症状不良事件的临床医生和患者报告:使用CTCAE和PRO-CTCAE提供两种不同且互补的观点。
Patient Relat Outcome Meas. 2022 Dec 8;13:249-258. doi: 10.2147/PROM.S256567. eCollection 2022.

本文引用的文献

1
Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.将患者体验纳入美国、欧洲和加拿大的监管决策中。
Lancet Oncol. 2018 May;19(5):e267-e274. doi: 10.1016/S1470-2045(18)30097-4.
2
Patient-reported tolerability of adverse events in phase 1 trials.患者报告的1期试验中不良事件的耐受性。
ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017.
3
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.一项评估常规癌症治疗期间症状监测的患者报告结局的试验的总生存结果。
JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156.
4
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.在一项放化疗协作组多中心临床试验中,通过患者报告的不良事件通用术语标准(PRO-CTCAE)让患者报告症状性不良事件的可行性。
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.
5
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.多中心癌症临床试验中患者报告症状性不良事件的可行性评估。
JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.
6
Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).癌症临床试验中的患者报告结局:使用美国国立癌症研究所不良事件通用术语标准的患者报告结局版本(PRO-CTCAE)测量症状性不良事件。
Am Soc Clin Oncol Educ Book. 2016;35:67-73. doi: 10.1200/EDBK_159514.
7
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局(PRO-CTCAE)的平板电脑、交互式语音应答系统和纸质管理方式的模式等效性与可接受性
Health Qual Life Outcomes. 2016 Feb 19;14:24. doi: 10.1186/s12955-016-0426-6.
8
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.常规癌症治疗期间通过患者报告结局进行症状监测:一项随机对照试验。
J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
9
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.在一项2期癌症治疗试验期间,与临床研究人员共享患者报告的症状毒性和体能状态的可行性及临床影响。
Clin Trials. 2016 Jun;13(3):331-7. doi: 10.1177/1740774515615540. Epub 2015 Nov 4.
10
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.